Novel Dyskerin-Mediated Mechanism of p53 Inactivation through Defective mRNA Translation

• Published in: Cancer research (Chicago, Ill.) Ill.), 2010-06, Vol.70 (11), p.4767-4777
• Main Authors: MONTANARO, Lorenzo, CALIENNI, Maria, BRIGOTTI, Maurizio, BONAFE, Massimiliano, TRERE, Davide, DERENZINI, Massimo, BERTONI, Sara, ROCCHI, Laura, SANSONE, Pasquale, STORCI, Gianluca, SANTINI, Donatella, CECCARELLI, Claudio, TAFFURELLI, Mario, CARNICELLI, Domenica
• Format: Article
• Language: English
• Subjects: Antineoplastic agents; Biological and medical sciences; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Cell Cycle Proteins - biosynthesis; Cell Cycle Proteins - genetics; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; Humans; Medical sciences; Nuclear Proteins - biosynthesis; Nuclear Proteins - deficiency; Nuclear Proteins - genetics; Pharmacology. Drug treatments; Protein Biosynthesis; RNA, Messenger - genetics; RNA, Messenger - metabolism; Telomerase - metabolism; Tumor Suppressor Protein p53 - biosynthesis; Tumor Suppressor Protein p53 - genetics; Tumors
• ISSN: 0008-5472; 1538-7445; 1538-7445
• DOI: 10.1158/0008-5472.can-09-4024

In up to 60% of human cancers, p53 gene mutations are responsible for direct inactivation of the tumor suppressor function of p53. Alternative mechanisms of p53 inactivation described thus far mainly affect its posttranslational regulation. In X-linked dyskeratosis congenita, a multisystemic syndrome characterized by increased cancer susceptibility, mutations of the DKC1 gene encoding dyskerin cause a selective defect in the translation of a subgroup of internal ribosome entry site (IRES)-containing cellular mRNAs. In this study, we show that impairment of dyskerin function can cause p53 inactivation due to a defect in p53 mRNA translation. siRNA-mediated reduction of dyskerin levels caused a decrease of p53 mRNA translation, protein levels, and functional activity, both in human breast cancer cells and in primary mammary epithelial progenitor cells. These effects seemed to be independent of the known role of dyskerin in telomerase function, and they were associated with a specific impairment of translation initiation mediated by IRES elements present in p53 mRNA. In a series of human primary breast cancers retaining wild-type p53, we found that low levels of dyskerin expression were associated with reduced expression of p53-positive target genes. Our findings suggest that a dyskerin-mediated mechanism of p53 inactivation may occur in a subset of human tumors.